Ischemia-Mediated Dysfunction in Subpapillary Myocardium as a Marker of Functional Mitral Regurgitation.
cardiac magnetic resonance
ischemia
mitral regurgitation
Journal
JACC. Cardiovascular imaging
ISSN: 1876-7591
Titre abrégé: JACC Cardiovasc Imaging
Pays: United States
ID NLM: 101467978
Informations de publication
Date de publication:
04 2021
04 2021
Historique:
received:
13
08
2020
revised:
28
12
2020
accepted:
06
01
2021
pubmed:
22
3
2021
medline:
28
8
2021
entrez:
21
3
2021
Statut:
ppublish
Résumé
The goal of this study was to test whether ischemia-mediated contractile dysfunction underlying the mitral valve affects functional mitral regurgitation (FMR) and the prognostic impact of FMR. FMR results from left ventricular (LV) remodeling, which can stem from myocardial tissue alterations. Stress cardiac magnetic resonance can assess ischemia and infarction in the left ventricle and papillary muscles; relative impact on FMR is uncertain. Vasodilator stress cardiac magnetic resonance was performed in patients with known or suspected coronary artery disease at 7 sites. Images were centrally analyzed for MR etiology/severity, mitral apparatus remodeling, and papillary ischemia. A total of 8,631 patients (mean age 60.0 ± 14.1 years; 55% male) were studied. FMR was present in 27%, among whom 16% (n = 372) had advanced (moderate or severe) FMR. Patients with ischemia localized to subpapillary regions were more likely to have advanced FMR (p = 0.003); those with ischemia localized to other areas were not (p = 0.17). Ischemic/dysfunctional subpapillary myocardium (odds ratio: 1.24/10% subpapillary myocardium; confidence interval: 1.17 to 1.31; p < 0.001) was associated with advanced FMR controlling for infarction. Among a subgroup with (n = 372) and without (n = 744) advanced FMR matched (1:2) on infarct size/distribution, patients with advanced FMR had increased adverse mitral apparatus remodeling, paralleled by greater ischemic/dysfunctional subpapillary myocardium (p < 0.001). Although posteromedial papillary ischemia was more common with advanced FMR (p = 0.006), subpapillary ischemia with dysfunction remained associated (p < 0.001), adjusting for posteromedial papillary ischemia (p = 0.074). During follow-up (median 5.1 years), 1,473 deaths occurred in the overall cohort; advanced FMR conferred increased mortality risk (hazard ratio: 1.52; 95% confidence interval: 1.25 to 1.86; p < 0.001) controlling for left ventricular ejection fraction, infarction, and ischemia. Ischemic and dysfunctional subpapillary myocardium provides a substrate for FMR, which predicts mortality independent of key mechanistic substrates.
Sections du résumé
OBJECTIVES
The goal of this study was to test whether ischemia-mediated contractile dysfunction underlying the mitral valve affects functional mitral regurgitation (FMR) and the prognostic impact of FMR.
BACKGROUND
FMR results from left ventricular (LV) remodeling, which can stem from myocardial tissue alterations. Stress cardiac magnetic resonance can assess ischemia and infarction in the left ventricle and papillary muscles; relative impact on FMR is uncertain.
METHODS
Vasodilator stress cardiac magnetic resonance was performed in patients with known or suspected coronary artery disease at 7 sites. Images were centrally analyzed for MR etiology/severity, mitral apparatus remodeling, and papillary ischemia.
RESULTS
A total of 8,631 patients (mean age 60.0 ± 14.1 years; 55% male) were studied. FMR was present in 27%, among whom 16% (n = 372) had advanced (moderate or severe) FMR. Patients with ischemia localized to subpapillary regions were more likely to have advanced FMR (p = 0.003); those with ischemia localized to other areas were not (p = 0.17). Ischemic/dysfunctional subpapillary myocardium (odds ratio: 1.24/10% subpapillary myocardium; confidence interval: 1.17 to 1.31; p < 0.001) was associated with advanced FMR controlling for infarction. Among a subgroup with (n = 372) and without (n = 744) advanced FMR matched (1:2) on infarct size/distribution, patients with advanced FMR had increased adverse mitral apparatus remodeling, paralleled by greater ischemic/dysfunctional subpapillary myocardium (p < 0.001). Although posteromedial papillary ischemia was more common with advanced FMR (p = 0.006), subpapillary ischemia with dysfunction remained associated (p < 0.001), adjusting for posteromedial papillary ischemia (p = 0.074). During follow-up (median 5.1 years), 1,473 deaths occurred in the overall cohort; advanced FMR conferred increased mortality risk (hazard ratio: 1.52; 95% confidence interval: 1.25 to 1.86; p < 0.001) controlling for left ventricular ejection fraction, infarction, and ischemia.
CONCLUSIONS
Ischemic and dysfunctional subpapillary myocardium provides a substrate for FMR, which predicts mortality independent of key mechanistic substrates.
Identifiants
pubmed: 33744130
pii: S1936-878X(21)00067-X
doi: 10.1016/j.jcmg.2021.01.007
pmc: PMC8086776
mid: NIHMS1665395
pii:
doi:
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
826-839Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL141917
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL140092
Pays : United States
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128278
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL063348
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007854
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL151686
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL132011
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL128099
Pays : United States
Organisme : NHLBI NIH HHS
ID : R61 HL151355
Pays : United States
Organisme : NHLBI NIH HHS
ID : K23 HL102249
Pays : United States
Organisme : NHLBI NIH HHS
ID : R33 HL151355
Pays : United States
Commentaires et corrections
Type : CommentIn
Informations de copyright
Copyright © 2021 American College of Cardiology Foundation. All rights reserved.
Déclaration de conflit d'intérêts
Funding Support and Author Disclosures This study was supported by the National Institutes of Health grants R01 HL128278 (Drs. Weinsaft, Ratcliffe, Levine, and J. Kim), R01 HL128099 and R01 HL141917 (Dr. Levine), R01-HL63348 (Dr. Ratcliffe), K23 HL140092 (Dr. J. Kim), K23 HL132011 (Dr. Shenoy), and T32 HL7854-23 (Dr. Kochav). It was also funded by the Glorney-Raisbeck Fellowship/NY Academy of Medicine (Dr. Kochav). Dr. Judd has an equity interest. Dr. R. Kim serves on the Board of Directors. Mr. Cargile is an employee of Heart Imaging Technologies. Dr. Klem is a consultant for and receives speaker honorarium from Bayer; and receives funding from Medtronic. Dr. Karmpaliotis receives funding from Abbott Vascular, Boston Scientific, and Abiomed; and has equity in Saranas, Soundbite, and Traverse Vascular. Dr. Leon receives funding from Abbott Vascular, Boston Scientific, and Medtronic. Dr. Weinsaft has received speaker honoraria from GE Healthcare. All other authors have reported that they have no relationships relevant to the contents of this paper to disclose.
Références
J Am Coll Cardiol. 2015 Mar 24;65(11):1078-88
pubmed: 25790878
Lancet. 2012 Feb 4;379(9814):453-60
pubmed: 22196944
JAMA Cardiol. 2019 Mar 1;4(3):256-264
pubmed: 30735566
Circulation. 2005 Jan 25;111(3):295-301
pubmed: 15655133
N Engl J Med. 2016 May 19;374(20):1932-41
pubmed: 27040451
J Am Coll Cardiol. 2001 Feb;37(2):641-8
pubmed: 11216991
J Am Soc Echocardiogr. 2017 Apr;30(4):303-371
pubmed: 28314623
Am J Cardiol. 2014 Aug 1;114(3):355-61
pubmed: 24948494
Eur Heart J. 2007 Dec;28(23):2866-72
pubmed: 17971401
J Am Coll Cardiol. 1992 Apr;19(5):1101-5
pubmed: 1552101
JACC Cardiovasc Imaging. 2020 Jul;13(7):1489-1501
pubmed: 31864972
Circulation. 2010 Nov 30;122(22):2281-7
pubmed: 21098437
Eur Heart J. 2005 Sep;26(18):1860-5
pubmed: 16055492
PLoS One. 2012;7(7):e40491
pubmed: 22815751
JACC Cardiovasc Imaging. 2013 Feb;6(2):220-34
pubmed: 23489536
Circulation. 2001 Oct 16;104(16):1952-7
pubmed: 11602500
J Am Coll Cardiol. 2006 Apr 18;47(8):1630-8
pubmed: 16631001
N Engl J Med. 2019 Jun 20;380(25):2418-2428
pubmed: 31216398
Circulation. 2001 Apr 3;103(13):1759-64
pubmed: 11282907
Circ Cardiovasc Imaging. 2016 Jul;9(7):
pubmed: 27406842
Circ Cardiovasc Imaging. 2008 Sep;1(2):148-55
pubmed: 19808532